Fibroblast growth factor 23 levels associate with AKI and death in critical illness

Journal of the American Society of Nephrology

Volumn 28, Issue 6, 2017, Pages 1877-1885

  Leaf, David E ^a   Jacob, Kirolos A ^b   Srivastava, Anand ^a   Chen, Margaret E ^a   Christov, Marta ^c,d   Jüppner, Harald ^c   Sabbisetti, Venkata S ^a   Martin, Aline ^e   Wolf, Myles ^f   Waikar, Sushrut S ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

^d NEW YORK MEDICAL COLLEGE   (United States)

^e NORTHWESTERN UNIVERSITY   (United States)

^f DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

25 HYDROXYVITAMIN D; CALCITRIOL; CALCIUM; CREATININE; FIBROBLAST GROWTH FACTOR 23; PARATHYROID HORMONE; PHOSPHATE; SECALCIFEROL; VITAMIN D; VITAMIN D BINDING PROTEIN; BIOLOGICAL MARKER; FIBROBLAST GROWTH FACTOR;

ACUTE KIDNEY FAILURE; ADULT; ADVERSE OUTCOME; AGED; ARTICLE; CALCIUM BLOOD LEVEL; CLINICAL OUTCOME; COHORT ANALYSIS; COMPARATIVE STUDY; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CREATININE URINE LEVEL; CRITICAL ILLNESS; CRITICALLY ILL PATIENT; FEMALE; HOSPITAL ADMISSION; HOSPITAL MORTALITY; HUMAN; INTENSIVE CARE UNIT; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; PARATHYROID HORMONE BLOOD LEVEL; PHOSPHATE BLOOD LEVEL; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; PROTEIN URINE LEVEL; VITAMIN BLOOD LEVEL; BLOOD; MORTALITY; URINE;

ACUTE KIDNEY INJURY; AGED; BIOMARKERS; CRITICAL ILLNESS; FEMALE; FIBROBLAST GROWTH FACTORS; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES;

EID: 85021651094     PISSN: 10466673     EISSN: 15333450     Source Type: Journal    
DOI: 10.1681/ASN.2016080836     Document Type: Article

References (40)

1. Chertow GM, Burdick E, Honour M, Bonventre JV, Bates DW: Acute kidney injury, mortality, length of stay, and costs in hospitalized patients. J Am Soc Nephrol 16: 3365-3370, 2005.
2. Waikar SS, Curhan GC, Wald R, McCarthy EP, Chertow GM: Declining mortality in patients with acute renal failure, 1988 to 2002. J Am Soc Nephrol 17: 1143-1150, 2006.
3. Waikar SS, Liu KD, Chertow GM: The incidence and prognostic significance of acute kidney injury. Curr Opin Nephrol Hypertens 16: 227- 236, 2007.
4. Leaf DE, Wolf M, Waikar SS, Chase H, Christov M, Cremers S, Stern L: FGF-23 levels in patients with AKI and risk of adverse outcomes. Clin J Am Soc Nephrol 7: 1217-1223, 2012.
5. Leaf DE, Christov M, Jüppner H, Siew E, Ikizler TA, Bian A, Chen G, Sabbisetti VS, Bonventre JV, Cai X, Wolf M, Waikar SS: Fibroblast growth factor 23 levels are elevated and associated with severe acute kidney injury and death following cardiac surgery. Kidney Int 89: 939- 948, 2016.
6. Christov M, Waikar SS, Pereira RC, Havasi A, Leaf DE, Goltzman D, Pajevic PD, Wolf M, Jüppner H: Plasma FGF23 levels increase rapidly after acute kidney injury. Kidney Int 84: 776-785, 2013.
7. Rossaint J, Oehmichen J, Van Aken H, Reuter S, Pavenstädt HJ, Meersch M, Unruh M, Zarbock A: FGF23 signaling impairs neutrophil recruitment and host defense during CKD. J Clin Invest 126: 962-974, 2016.
8. Singh S, Grabner A, Yanucil C, Schramm K, Czaya B, Krick S, Czaja MJ, Bartz R, Abraham R, Di Marco GS, Brand M, Wolf M, Faul C: Fibroblast growth factor 23 directly targets hepatocytes to promote inflammation in chronic kidney disease. Kidney Int 90: 985-996, 2016.
9. Bacchetta J, Sea JL, Chun RF, Lisse TS, Wesseling-Perry K, Gales B, Adams JS, Salusky IB, Hewison M: Fibroblast growth factor 23 inhibits extrarenal synthesis of 1, 25-dihydrox yvitamin D in human monocytes. J Bone Miner Res 28: 46-55, 2013.
10. Shimada T, Hasegawa H, Yamazaki Y, Muto T, Hino R, Takeuchi Y, Fujita T, Nakahara K, Fukumoto S, Yamashita T: FGF-23 is a potent regulator of vitamin D metabolism and phosphate homeostasis. J Bone Miner Res 19: 429-435, 2004.
11. Leaf DE, Waikar SS, Wolf M, Cremers S, Bhan I, Stern L: Dysregulated mineral metabolism in patients with acute kidney injury and risk of adverse outcomes. Clin Endocrinol (Oxf) 79: 491-498, 2013.
12. Ginde AA, Camargo CA Jr., Shapiro NI: Vitamin D insufficiency and sepsis severity in emergency department patients with suspected infection. Acad Emerg Med 18: 551-554, 2011.
13. Gutiérrez OM, Mannstadt M, Isakova T, Rauh-Hain JA, Tamez H, Shah A, Smith K, Lee H, Thadhani R, Jüppner H, Wolf M: Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis. N Engl J Med 359: 584-592, 2008.
14. Isakova T, Xie H, Yang W, Xie D, Anderson AH, Scialla J, Wahl P, GutiérrezOM, Steigerwalt S, He J, Schwartz S, Lo J, Ojo A, Sondheimer J, Hsu CY, Lash J, Leonard M, Kusek JW, Feldman HI, Wolf M; Chronic Renal Insufficiency Cohort (CRIC) Study Group: Fibroblast growth factor 23 and risks of mortality and end-stage renal disease in patients with chronic kidney disease. JAMA 305: 2432-2439, 2011.
15. Siew E D, Matheny M E: Choice of reference serumcreatinine in defining acute kidney injury. Nephron 131: 107-112, 2015.
16. Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF 3rd, Feldman HI, Kusek JW, Eggers P, Van Lente F, Greene T, Coresh J; CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration): A new equation to estimate glomerular filtration rate. Ann Intern Med 150: 604-612, 2009.
17. Kidney Disease Improving Global Outcomes (KDIGO) Acute Kidney Injury Work Group: KDIGO clinical practice guideline for acute kidney injury. Kidney Int Suppl 2: 1-138, 2012.
18. di Giuseppe R, Buijsse B, Hirche F, Wirth J, Arregui M, Westphal S, Isermann B, Hense HW, Dierkes J, Boeing H, Stangl GI, Weikert C: Plasma fibroblast growth factor 23, parathyroid hormone, 25-hydroxyvitamin D3, and risk of heart failure: A prospective, case-cohort study. J Clin Endocrinol Metab 99: 947-955, 2014.
19. Ix JH, Katz R, Kestenbaum BR, de Boer IH, Chonchol M, Mukamal KJ, Rifkin D, Siscovick D S, Sarnak MJ, ShlipakM G: Fibroblast growth factor- 23 and death, heart failure, and cardiovascular events in communityliving individuals: CHS (CardiovascularHealth Study). J AmColl Cardiol 60: 200-207, 2012.
20. Scialla JJ, Xie H, Rahman M, Anderson AH, Isakova T, Ojo A, Zhang X, Nessel L, Hamano T, Grunwald JE, Raj DS, Yang W, He J, Lash JP, Go AS, Kusek JW, Feldman H, Wolf M; Chronic Renal Insufficiency Cohort (CRIC) Study Investigators: Fibroblast growth factor-23 and cardiovascular events in CKD. J Am Soc Nephrol 25: 349-360, 2014.
21. Larsson T, Nisbeth U, Ljunggren O, Jüppner H, Jonsson KB: Circulating concentration of FGF-23 increases as renal function declines in patients with chronic kidney disease, but does not change in response to variation in phosphate intake in healthy volunteers. Kidney Int 64: 2272-2279, 2003.
22. Wesseling-Perry K, Pereira RC, Tsai E, Ettenger R, Jüppner H, Salusky IB: FGF23 and mineral metabolism in the early post-renal transplantation period. Pediatr Nephrol 28: 2207-2215, 2013.
23. Spichtig D, Zhang H, Mohebbi N, Pavik I, Petzold K, Stange G, Saleh L, Edenhofer I, Segerer S, Biber J, Jaeger P, Serra AL, Wagner CA: Renal expression of FGF23 and peripheral resistance to elevated FGF23 in rodent models of polycystic kidney disease. Kidney Int 85: 1340-1350, 2014.
24. Zanchi C, Locatelli M, Benigni A, Corna D, Tomasoni S, Rottoli D, Gaspari F, Remuzzi G, Zoja C: Renal expression of FGF23 in progressive renal disease of diabetes and the effect of ACE inhibitor. PLoS One 8: E70775, 2013.
25. Rabkin R, Ryan MP, Duckworth WC: The renal metabolism of insulin. Diabetologia 27: 351-357, 1984.
26. van Ballegooijen AJ, Rhee EP, Elmariah S, de Boer IH, Kestenbaum B: Renal clearance of mineral metabolism biomarkers. J Am Soc Nephrol 27: 392-397, 2016.
27. Mace ML, Gravesen E, Hofman-Bang J, Olgaard K, Lewin E: Key role of the kidney in the regulation of fibroblast growth factor 23. Kidney Int 88: 1304-1313, 2015.
28. Faul C, Amaral AP, Oskouei B, Hu MC, Sloan A, Isakova T, Gutiérrez OM, Aguillon-Prada R, Lincoln J, Hare JM, Mundel P, Morales A, Scialla J, FischerM, Soliman EZ, Chen J, Go AS, Rosas SE, Nessel L, Townsend RR, Feldman HI, St John Sutton M, Ojo A, Gadegbeku C, DiMarco GS, Reuter S, Kentrup D, Tiemann K, BrandM, Hill JA, MoeOW, Kuro-OM, Kusek JW, Keane MG, Wolf M: FGF23 induces left ventricular hypertrophy. J Clin Invest 121: 4393-4408, 2011.
29. Grabner A, Amaral AP, Schramm K, Singh S, Sloan A, Yanucil C, Li J, Shehadeh LA, Hare JM, David V, Martin A, Fornoni A, Di Marco GS, Kentrup D, Reuter S, Mayer AB, Pavenstädt H, Stypmann J, Kuhn C, Hille S, Frey N, Leifheit-Nestler M, Richter B, Haffner D, Abraham R, Bange J, Sperl B, Ullrich A, Brand M, Wolf M, Faul C: Activation of cardiac fibroblast growth factor receptor 4 causes left ventricular hypertrophy. Cell Metab 22: 1020-1032, 2015.
30. Hasegawa H, Nagano N, Urakawa I, Yamazaki Y, Iijima K, Fujita T, Yamashita T, Fukumoto S, Shimada T: Direct evidence for a causative role of FGF23 in the abnormal renal phosphate handling and vitamin D metabolism in rats with early-stage chronic kidney disease. Kidney Int 78: 975-980, 2010.
31. Inoue Y, Segawa H, Kaneko I, Yamanaka S, Kusano K, Kawakami E, Furutani J, ItoM, Kuwahata M, Saito H, Fukushima N, Kato S, Kanayama HO, Miyamoto K: Role of the vitamin D receptor in FGF23 action on phosphate metabolism. Biochem J 390: 325-331, 2005.
32. Bacchetta J, Sea JL, Chun RF, Lisse TS, Wesseling-Perry K, Gales B, Adams JS, Salusky IB, Hewison M: FGF23 inhibits extra-renal synthesis of 1, 25- dihydroxyvitaminDin human monocytes. J BoneMiner Res 28: 46-55: 2013.
33. Arnson Y, Gringauz I, Itzhaky D, Amital H: Vitamin D deficiency is associated with poor outcomes and increased mortality in severely ill patients. QJM 105: 633-639, 2012.
34. Braun A, Chang D, Mahadevappa K, Gibbons FK, Liu Y, Giovannucci E, Christopher KB: Association of low serum 25-hydroxyvitamin D levels and mortality in the critically ill. Crit Care Med 39: 671-677, 2011.
35. Matthews LR, Ahmed Y, Wilson KL, Griggs DD, Danner OK: Worsening severity of vitamin D deficiency is associated with increased length of stay, surgical intensive care unit cost, and mortality rate in surgical intensive care unit patients. Am J Surg 204: 37-43, 2012.
36. Bai X, Miao D, Xiao S, Qiu D, St-Arnaud R, Petkovich M, Gupta A, Goltzman D, Karaplis AC:CYP24 inhibition as a therapeutic target inFGF23-mediated renal phosphate wasting disorders. J Clin Invest 126: 667-680, 2016.
37. Wolf M, White K E: Couplingfibroblast growth factor 23 production and cleavage: Iron deficiency, rickets, and kidney disease. Curr Opin Nephrol Hypertens 23: 411-419, 2014.
38. Strathmann FG, Laha TJ, Hoofnagle AN: Quantification of 1a, 25-dihydroxy vitamin D by immunoextraction and liquid chromatography-Tandem mass spectrometry. Clin Chem 57: 1279-1285, 2011.
39. Levy MM, Fink MP, Marshall JC, AbrahamE, Angus D, CookD, Cohen J, Opal SM, Vincent JL, Ramsay G; SCCM/ESICM/ACCP/ATS/SIS: 2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference. Crit Care Med 31: 1250-1256, 2003.
40. Rubenfeld GD, Angus DC, Pinsky MR, Curtis JR, Connors AF Jr., Bernard GR: Outcomes research in critical care: Results of the American Thoracic Society Critical Care Assembly Workshop on outcomes research. The Members of the Outcomes Research Workshop. Am J Respir Crit Care Med 160: 358-367, 1999.